Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BMN 349 in Alpha 1-Antitrypsin Deficiency
NCT06738017Phase 1Active, not recruiting
- Sponsor
- BioMarin Pharmaceutical
- Start
- Feb 2025
- Primary completion
- Aug 2026
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, randomised, double-blind trial of BMN 349 in alpha-1 antitrypsin deficiency (AATD) (2 arms), sponsored by BioMarin Pharmaceutical. Primary endpoints: Adverse Events at 78 days, Abnormal Laboratory Tests at 78 days and 2 more. Started Feb 2025; status: active, not recruiting.
02
Drugs
BMN 349
03
Conditions
alpha-1 antitrypsin deficiency (AATD)
Beyond the preview
Go deeper on NCT06738017.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06738017.